Rebamipide-d4 is intended for use as an internal standard for the quantification of rebamipide by GC- or LC-MS. Rebamipide is a gastroprotective agent and mucin secretagogue.1,2 It increases the levels of prostaglandin E2 and COX-2 in rat gastric mucosa when administered at doses of 15 and 50 mg/kg per day. Rebamipide (30 and 100 mg/kg, i.p.) prevents the formation of gastric ulcers induced by absolute ethanol, sodium hydroxide, or hydrochloric acid in rats, an effect that can be blocked by the non-selective COX inhibitor indomethacin .3 It also increases the production of mucin 16 in stratified corneal epithelial cells in vitro when used at concentrations of 10 and 100 ?M.2 Rebamipide (1% w/v) increases the levels of mucin-like substances in rabbit conjunctiva and cornea and, in a rabbit model of dry eye disease, reduces desiccation-induced corneal damage.4 Formulations containing rebamipide have been used in the treatment of peptic ulcer disease and dry eye disease.
1.Sun, W.H., Tsuji, S., Gunawan, E.S., et al.Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agentPharmacol. Exp. Ther.295(2)447-452(2000) 2.Uchino, Y., Woodward, A.M., and Argüeso, P.Differential effect of rebamipide on transmembrane mucin biosynthesis in stratified ocular surface epithelial cellsExp. Eye Res.1531-7(2016) 3.Yamasaki, K., Kanbe, T., Chijiwa, T., et al.Gastric mucosal protection by OPC-12759, a novel antiulcer compound, in the ratEur. J. Pharmacol.142(1)23-29(1987) 4.Urashima, H., Takeji, Y., Okamato, T., et al.Rebamipide increases mucin-like substance contents and periodic acid Schiff reagent-positive cells density in normal rabbitsJ. Ocul. Pharmacol. Ther.28(3)264-270(2012)